Evidence map›Paper›PMID 37627927›Full record

ArticleDiagnostics (Basel, Switzerland)2023

Identification of Radiomic Signatures in Brain MRI Sequences T1 and T2 That Differentiate Tumor Regions of Midline Gliomas with H3.3K27M Mutation.

Maria-Fatima Chilaca-Rosas, Manuel-Tadeo Contreras-Aguilar, Melissa Garcia-Lezama, David-Rafael Salazar-Calderon, Raul-Gabriel Vargas-Del-Angel, Sergio Moreno-Jimenez, Patricia Piña-Sanchez, Raul-Rogelio Trejo-Rosales, Felipe-Alfredo Delgado-Martinez, Ernesto Roldan-Valadez

Open access · goldAbstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Maria-Fatima Chilaca-RosasRadiotherapy Department, Hospital de Oncología, Centro Medico Nacional Siglo XXI, Instituto Mexicano Del Seguro Social, Mexico City 06720, Mexico.
Manuel-Tadeo Contreras-AguilarRadiotherapy Department, Hospital de Oncología, Centro Medico Nacional Siglo XXI, Instituto Mexicano Del Seguro Social, Mexico City 06720, Mexico.ORCID 0000-0001-8799-6426
Melissa Garcia-LezamaDirectorate of Research, Hospital General de Mexico Dr Eduardo Liceaga, Mexico City 06720, Mexico.ORCID 0000-0002-6018-6244
David-Rafael Salazar-CalderonRadiotherapy Department, Hospital de Oncología, Centro Medico Nacional Siglo XXI, Instituto Mexicano Del Seguro Social, Mexico City 06720, Mexico.ORCID 0000-0002-3924-7508
Raul-Gabriel Vargas-Del-AngelDepartment of Internal Medicine, Hospital General de Mexico Dr Eduardo Liceaga, Mexico City 06720, Mexico.ORCID 0000-0002-1805-6032
Sergio Moreno-JimenezNeurological Center, Neurosurgery Department of National Institute of Neurology and Neurosurgery, Mexico City 14269, Mexico.ORCID 0000-0001-9932-0917
Patricia Piña-SanchezOncology Diagnostic, Unidad de Investigacion Medica en Enfermedades Oncologicas U.I.M.E.O, Hospital de Oncología, Centro Medico Nacional Siglo XXI, Instituto Mexicano Del Seguro Social, Mexico City 06720, Mexico.ORCID 0000-0002-5890-1931
Raul-Rogelio Trejo-RosalesMedical Oncology, Hospital de Oncología, Centro Medico Nacional Siglo XXI, Instituto Mexicano Del Seguro Social, Mexico City 06720, Mexico.
Felipe-Alfredo Delgado-MartinezMagnetic Resonance Service, Hospital de Especialidades, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City 06720, Mexico.ORCID 0000-0002-6776-5177
Ernesto Roldan-ValadezDirectorate of Research, Hospital General de Mexico Dr Eduardo Liceaga, Mexico City 06720, Mexico.ORCID 0000-0002-7116-5289
Centro Medico Nacional Siglo XXI · MXHospital General de México · MXCentro Médico ABC · MXMexican Social Security Institute · MXSechenov University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRadiomics refers to the acquisition of traces of quantitative features that are usually non-perceptible to human vision and are obtained from different imaging techniques and subsequently transformed into high-dimensional data. Diffuse midline gliomas (DMG) represent approximately 20% of pediatric CNS tumors, with a median survival of less than one year after diagnosis. We aimed to identify which radiomics can discriminate DMG tumor regions (viable tumor and peritumoral edema) from equivalent midline normal tissue (EMNT) in patients with the positive H3.F3K27M mutation, which is associated with a worse prognosis. PATIENTS AND

methodsThis was a retrospective study. From a database of 126 DMG patients (children, adolescents, and young adults), only 12 had H3.3K27M mutation and available brain magnetic resonance DICOM file. The MRI T1 post-gadolinium and T2 sequences were uploaded to LIFEx software to post-process and extract radiomic features. Statistical analysis included normal distribution tests and the Mann-Whitney U test performed using IBM SPSS

resultsEMNT vs. Tumor: From the T1 sequence 10 radiomics were identified, and 14 radiomics from the T2 sequence, but only one radiomic identified viable tumors in both sequences (

conclusionsLess than 5% of the radiomic characteristics identified tumor regions of medical-clinical interest in T1 and T2 sequences of conventional magnetic resonance imaging. The first-order and second-order radiomic features suggest support to investigators and clinicians for careful evaluation for diagnosis, patient classification, and multimodality cancer treatment planning.

Indexed as

brain tumormidline gliomasMRIradiomics

Identifiers

PMID37627927
PMCPMC10453217
OpenAlexW4385795939

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.